Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL): what makes T-ALL TYK?

Research output: Contribution to journal › Editorial › Other › peer-review

Original language	English
Pages (from-to)	169-170
Number of pages	2
Journal	British Journal of Haematology
Volume	177
Issue number	2
DOIs	https://doi.org/10.1111/bjh.14559
Publication status	Published - 1 Apr 2017

Keywords

@article{a95405531c8a4c70abff6dc26fac4d18,

title = "Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL): what makes T-ALL TYK?",

keywords = "inhibitor, T-cell acute lymphoblastic leukaemia, TYK2",

author = "Curtis, {David J.}",

year = "2017",

month = apr,

day = "1",

doi = "10.1111/bjh.14559",

language = "English",

volume = "177",

pages = "169--170",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley & Sons",

number = "2",

}

TY - JOUR

T1 - Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL)

T2 - what makes T-ALL TYK?

AU - Curtis, David J.

PY - 2017/4/1

Y1 - 2017/4/1

KW - inhibitor

KW - T-cell acute lymphoblastic leukaemia

KW - TYK2

UR - http://www.scopus.com/inward/record.url?scp=85013480732&partnerID=8YFLogxK

U2 - 10.1111/bjh.14559

DO - 10.1111/bjh.14559

M3 - Editorial

AN - SCOPUS:85013480732

VL - 177

SP - 169

EP - 170

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -